DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy | Zendy

Markus Alter | Zendy; Ina M. Ott | Zendy; Karoline von Websky | Zendy; Oleg Tsuprykov | Zendy; Yuliya Sharkovska | Zendy; Katharina Krause-Relle | Zendy; Jens Raila | Zendy; Andrea Henze | Zendy; Thomas Klein | Zendy; Berthold Hocher | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy

Author(s) -

Markus Alter,

Ina M. Ott,

Karoline von Websky,

Oleg Tsuprykov,

Yuliya Sharkovska,

Katharina Krause-Relle,

Jens Raila,

Andrea Henze,

Thomas Klein,

Berthold Hocher

Publication year - 2012

Publication title -

kidney and blood pressure research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.806

H-Index - 51

eISSN - 1423-0143

pISSN - 1420-4096

DOI - 10.1159/000341487

Subject(s) - telmisartan , linagliptin , medicine , diabetic nephropathy , endocrinology , enos , diabetes mellitus , irbesartan , streptozotocin , blood pressure , nephropathy , losartan , valsartan , angiotensin receptor , albuminuria , pharmacology , angiotensin ii , type 2 diabetes , nitric oxide , nitric oxide synthase

The need for an improved treatment for diabetic nephropathy is greatest in patients who do not adequately respond to angiotensin II receptor blockers (ARBs). This study investigated the effect of the novel dipeptidyl peptidase-4 inhibitor linagliptin alone and in combination with the ARB telmisartan on the progression of diabetic nephropathy in diabetic endothelial nitric oxide synthase (eNOS) knockout mice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research